RASSF1 and hepatocellular carcinoma: Therefore, in addition to its diagnostic value, RASSF1A promoter hypermethylation may also be used as a valuable prognostic marker and an emerging target for anti-HCC treatment; further high-quality, well-designed prospective studies are needed to confirm the same.